An observational study in Preterm Birth, sponsored by Maternal and Child Health Hospital, Jiading District. Completed at 1 site in China. Open to female participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2026-09-28.
Sponsored by Maternal and Child Health Hospital, Jiading District · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 79 studies in Premature Birth with a site in China — 26 open to participants now, 31 under way, 2 of them phase 3. Premature Birth · China.
Among the 79 studies in Premature Birth with a site in China, this one is the 19th largest by enrollment of the 35 observational ones that give a count, is one of 9 that started in 2020, is one of 35 observational ones, and was the 79th registered.
2,557 studies on the registry are indexed under Premature Birth; 504 are open to participants now.
Browse Premature Birth studies →26 of the 79 studies in Premature Birth with a site in China are open now. Recruiting first, the newest first:
Shanghai Jiao Tong University School of Medicine · Sites in China
Ages 0 days+
Guangzhou Women and Children's Medical Center · Sites in China
Ages up to 12 mo
Children's Hospital of Fudan University · Sites in China
Ages up to 1 days
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University · Sites in China
Ages 1 min–1 hrs
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine · Sites in China
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 318 Premature Birth studies recruiting now, 88 (28%) set no upper age limit and 226 (71%) stop at 75 or younger; 243 take children under 18; 104 take healthy volunteers.
This study: 18 Years to 45 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
79 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 7 · Phase 3 5 · Phase 4 8
First in 2006; this study’s year is marked. 9 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 436 is above the median of 120 across 809 observational studies indexed under Premature Birth.
Median enrollment 195 across the 44 interventional studies, 541 across the 35 observational. Of the 31 that completed or were terminated, 1 (3%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 79 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Maternal and Child Health Hospital, Jiading District as lead sponsor.
Maternal and Child Health Hospital, Jiading District has 1 study filed under Premature Birth — fewer than ten, so there is no comparison to draw.
9 of the studies in Premature Birth with a site in China that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03168516Phase 3University Hospital TuebingenEffects of Closed-loop Automatic Control of FiO2 in Extremely Preterm Infants | 2026-12 |
| NCT06414655Peking University Third HospitalMulticenter Prospective Cohort Study of Twin Maternal-Child Dyads in China | 2026-11-30 |
| NCT07756177Sun Yat-sen UniversityGuangzhou Preterm and Term Birth Cohort Study | 2026-12-31 |
| NCT06234332Peking UniversityPeking University Birth Cohort in Weifang (PKUBC-WF) | 2026-12-31 |
| NCT04777760Daping Hospital and the Research Institute of Surgery of the Third Military Medical UniversitySurfactant for Neonatal Respiratory Distress Syndrome(NRDS) and Neonatal Acute Respiratory Distress Syndrome(NARDS) | 2026-12-31 |
Add all 9 to your calendar (.ics) → With an account.
Among the 79 studies in Premature Birth with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This retrospective observational study evaluates labor characteristics in primiparous women with spontaneous preterm birth at different gestational ages and examines their associations with maternal and neonatal outcomes. Medical records of women who delivered at Shanghai Jiading District Maternity and Child Health Care Hospital between January 1, 2020, and December 31, 2025, are reviewed.
Participants are classified according to gestational age at delivery into very preterm (28 to 31+6 weeks), moderate preterm (32 to 33+6 weeks), and late preterm (34 to 36+6 weeks) groups. The study compares the onset and duration of the active phase of labor, cervical dilation rate, and durations of the first and second stages of labor across these gestational-age groups.
The study also evaluates the associations between labor duration and maternal and neonatal outcomes, including postpartum blood loss, mode of vaginal delivery, and 5-minute Apgar score. The findings are intended to provide evidence for gestational age-specific and individualized labor management in women with spontaneous preterm birth.
This is a single-center, retrospective observational study based on electronic medical records from Shanghai Jiading District Maternity and Child Health Care Hospital. The study population consists of primiparous women with spontaneous preterm birth at 28 to 36+6 weeks of gestation who delivered vaginally between January 1, 2020, and December 31, 2025.
Participants are categorized into three gestational-age groups: very preterm (28 to 31+6 weeks), moderate preterm (32 to 33+6 weeks), and late preterm (34 to 36+6 weeks). Labor characteristics assessed include cervical dilation at the onset of the active phase, duration of the active phase, mean cervical dilation rate during the active phase, duration of the first stage of labor, and duration of the second stage of labor. The study also evaluates differences in labor duration according to the use of epidural labor analgesia.
Maternal and neonatal variables collected from the medical records include maternal age, gravidity, pre-pregnancy body mass index, gestational age at delivery, pregnancy-related complications and comorbidities, neonatal birth weight, vaginal delivery status, postpartum blood loss within 2 hours after delivery, postpartum hemoglobin level, and 5-minute Apgar score.
Associations between the durations of the first and second stages of labor and maternal or neonatal outcomes are evaluated using regression analyses with adjustment for relevant potential confounding variables. Linear regression is used to assess postpartum blood loss, multinomial logistic regression is used to evaluate vaginal delivery outcomes, and binary logistic regression is used to evaluate neonatal Apgar outcomes. Restricted cubic spline analyses are used to explore potential dose-response relationships between labor duration and outcomes showing statistically significant associations.
The study is non-interventional. All information is obtained retrospectively from existing medical records and is analyzed after de-identification.
Primiparous women with spontaneous preterm birth who delivered vaginally at Shanghai Jiading District Maternity and Child Health Care Hospital between January 1, 2020, and December 31, 2025, were identified retrospectively from the hospital electronic medical record system. Eligible women had a singleton pregnancy with vertex presentation and delivered between 28 weeks 0 days and 36 weeks 6 days of gestation. Participants were classified according to gestational age at delivery into very preterm, moderate preterm, and late preterm groups.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Primiparous women undergoing vaginal delivery.
Exclusion Criteria:
Primiparous women with spontaneous preterm birth who delivered vaginally at 28 weeks 0 days to 31 weeks 6 days of gestation. This group included 45 participants. No study-specific intervention was assigned; clinical and labor data were retrospectively obtained from existing medical records.
Other: Gestational Age at Delivery
Primiparous women with spontaneous preterm birth who delivered vaginally at 32 weeks 0 days to 33 weeks 6 days of gestation. This group included 37 participants. No study-specific intervention was assigned; clinical and labor data were retrospectively obtained from existing medical records.
Other: Gestational Age at Delivery
Primiparous women with spontaneous preterm birth who delivered vaginally at 34 weeks 0 days to 36 weeks 6 days of gestation. This group included 354 participants. No study-specific intervention was assigned; clinical and labor data were retrospectively obtained from existing medical records.
Other: Gestational Age at Delivery
Gestational age at delivery was the primary exposure of interest. Participants were retrospectively classified into three groups according to gestational age at delivery: very preterm (28 weeks 0 days to 31 weeks 6 days), moderate preterm (32 weeks 0 days to 33 weeks 6 days), and late preterm (34 weeks 0 days to 36 weeks 6 days). No study-specific intervention was assigned, and all exposure and outcome information was obtained from existing medical records.
Duration of the Active Phase of Labor
Duration of the active phase of labor, measured in hours, from the onset of the active phase to full cervical dilation (10 cm). The onset of the active phase was defined as the cervical dilation corresponding to the inflection point at which the cervical dilation curve changed from a gradual slope to its maximum slope.
Time frame: During labor, from the identified onset of the active phase to full cervical dilation (10 cm)
Title Description Time Frame Cervical Dilation at the Onset of the Active Phase
Cervical dilation, measured in centimeters, at the identified onset of the active phase of labor.
Time frame: At onset of the active phase during the index delivery
Mean Cervical Dilation Rate During the Active Phase
Mean cervical dilation rate, measured in cm/hour, calculated as (10 cm minus cervical dilation at the onset of the active phase) divided by the duration of the active phase.
Time frame: During labor, from the identified onset of the active phase to full cervical dilation (10 cm)
Duration of the First Stage of Labor
Duration of the first stage of labor, measured in hours, as documented in the obstetric medical record.
Time frame: During labor, from the documented onset of labor to full cervical dilation (10 cm)
Duration of the Second Stage of Labor
Duration of the second stage of labor, measured in hours, from full cervical dilation to delivery of the fetus.
Time frame: During labor, from full cervical dilation (10 cm) to fetal delivery
Postpartum Blood Loss Within 2 Hours After Delivery
Postpartum blood loss within 2 hours after delivery, measured in milliliters using the gravimetric weighing method and documented in the medical record.
Time frame: From fetal delivery through 2 hours postpartum
Vaginal Delivery Status
Vaginal delivery status categorized as spontaneous vaginal delivery, episiotomy, or forceps-assisted vaginal delivery, as documented in the medical record.
Time frame: At the time of delivery
5-Minute Apgar Score
Neonatal Apgar score assessed 5 minutes after birth and documented in the medical record. The score was evaluated to assess neonatal condition after delivery.
Time frame: 5 minutes after birth
Plan to share: Yes — De-identified individual participant data underlying the reported study results may be shared with qualified researchers upon reasonable request to the corresponding author. The shared data may include relevant maternal characteristics, gestational age at delivery, labor characteristics, maternal outcomes, and neonatal outcomes. No directly identifiable participant information will be provided. Data sharing will be subject to institutional approval and applicable privacy and data protection requirements.
Supporting information: Study protocol
Time frame: Data will be available beginning after publication of the primary study results and will remain available in accordance with the institution's data retention and governance policies.
Access criteria: Qualified researchers may request access to the de-identified individual participant data from the corresponding author for legitimate scientific research purposes. Requests will be reviewed on a case-by-case basis by the study investigators and, where required, the institution. Access will be subject to institutional approval and applicable privacy, confidentiality, and data protection requirements.
No publications or documents are linked to this record.
Ran from Jan 2020 to primary completion in Dec 2025, 71 months.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.